公开(公告)号：US20240175086A1

公开(公告)日：2024-05-30

申请号：US18521390

申请日：2023-11-28

Applicant: Genentech, Inc.

Inventor： David F. CHOY ,  Tracy Lyn STATON ,  Brian Louis YASPAN

IPC: C12Q1/6883 ,  A61K31/522 ,  A61K45/06

CPC classification number: C12Q1/6883 ,  A61K31/522 ,  A61K45/06 ,  A61K2039/505

Abstract: The present invention features, inter alia, methods of treating patients having a mast cell-mediated inflammatory disease, methods of determining whether patients having a mast cell-mediated inflammatory disease are likely to respond to a therapy (e.g., a therapy comprising an agent selected from the group consisting of a tryptase antagonist, an Fc epsilon receptor (FcεR) antagonist, an IgE+ B cell depleting antibody, a mast cell or basophil depleting antibody, a protease activated receptor 2 (PAR2) antagonist, an IgE antagonist, and a combination thereof), methods of selecting a therapy for a patient having a mast cell-mediated inflammatory disease, methods for assessing a response of a patient having mast cell-mediated inflammatory disease, and methods for monitoring the response of a patient having a mast cell-mediated inflammatory disease.

公开(公告)号：US20200377953A1

公开(公告)日：2020-12-03

申请号：US16987958

申请日：2020-08-07

Applicant: Genentech, Inc.

Inventor： David F. CHOY ,  Tracy Lyn STATON ,  Brian Louis YASPAN

IPC: C12Q1/6883 ,  C07K16/42 ,  A61K39/395 ,  A61K45/06 ,  A61P11/06 ,  G01N33/573 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/522 ,  A61K31/505 ,  A61K31/519

Abstract: The present invention features, inter alia, methods of treating patients having a mast cell-mediated inflammatory disease, methods of determining whether patients having a mast cell-mediated inflammatory disease are likely to respond to a therapy (e.g., a therapy comprising an agent selected from the group consisting of a tryptase antagonist, an Fc epsilon receptor (FcεR) antagonist, an IgE+ B cell depleting antibody, a mast cell or basophil depleting antibody, a protease activated receptor 2 (PAR2) antagonist, an IgE antagonist, and a combination thereof), methods of selecting a therapy for a patient having a mast cell-mediated inflammatory disease, methods for assessing a response of a patient having mast cell-mediated inflammatory disease, and methods for monitoring the response of a patient having a mast cell-mediated inflammatory disease.